Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
2.
J Clin Endocrinol Metab ; 94(7): 2406-13, 2009 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-19383776

RESUMO

CONTEXT: Primary pigmented nodular adrenocortical disease (PPNAD) results in most cases from mutations of the protein kinase A (PKA) regulatory subunit 1A (PRKAR1A) gene. Patients with PPNAD exhibit a paradoxical increase in cortisol secretion in response to dexamethasone. OBJECTIVE: The aim was to investigate the mechanism of the action of dexamethasone on adrenocortical cells removed from patients with PPNAD and a transgenic model of PPNAD [Tg(tTA/X2AS) mice]. DESIGN AND SETTING: We performed an in vitro study in an academic research laboratory. PATIENTS: Eleven patients with histologically proven PPNAD were included in the study. INTERVENTION: Cultured PPNAD cells were incubated with dexamethasone in the presence of various modulators of the cAMP/PKA pathway and the glucocorticoid receptor antagonist RU486. MAIN OUTCOME MEASURE: Cortisol and corticosterone were measured by radioimmunological assays in cell culture supernatants. RESULTS: Dexamethasone stimulated in vitro cortisol secretion from PPNAD tissues in six patients. The stimulatory effect of dexamethasone on cortisol release was not reduced by the adenylyl cyclase inhibitor SQ22536 or potentiated by the phosphodiesterase inhibitor IMBX and the cAMP analog 8Br-cAMP. Conversely, the PKA inhibitor H89 and RU486 inhibited the cortisol response to dexamethasone. Dexamethasone had no effect on cortisol production from normal human adrenocortical cells but stimulated corticosteroidogenesis in the presence of RU486. Similarly, dexamethasone failed to influence corticosterone release by adrenocortical cells removed from Tg(tTA/X2AS) mice but stimulated corticosteroidogenesis in the presence of RU 486. CONCLUSIONS: These results indicate that, in human PPNAD tissues, dexamethasone paradoxically stimulates cortisol release through a glucocorticoid receptor-mediated effect on PKA catalytic subunits.


Assuntos
Doenças do Córtex Suprarrenal/metabolismo , Subunidades Catalíticas da Proteína Quinase Dependente de AMP Cíclico/genética , Dexametasona/farmacologia , Hidrocortisona/metabolismo , Transtornos da Pigmentação/metabolismo , Receptores de Glucocorticoides/fisiologia , Adolescente , Doenças do Córtex Suprarrenal/complicações , Doenças do Córtex Suprarrenal/genética , Adulto , Animais , Células Cultivadas , Criança , Pré-Escolar , Subunidades Catalíticas da Proteína Quinase Dependente de AMP Cíclico/metabolismo , Feminino , Regulação Enzimológica da Expressão Gênica/efeitos dos fármacos , Humanos , Masculino , Camundongos , Camundongos Transgênicos , Pessoa de Meia-Idade , Transtornos da Pigmentação/complicações , Transtornos da Pigmentação/genética , Receptores de Glucocorticoides/metabolismo , Regulação para Cima/efeitos dos fármacos , Adulto Jovem
3.
J Clin Endocrinol Metab ; 91(4): 1566-72, 2006 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-16449345

RESUMO

CONTEXT: Arginine vasopressin (AVP) stimulates steroid secretion from the normal human adrenal gland and some cortisol-producing adrenocortical tumors or hyperplasia through activation of the V(1a) receptor. OBJECTIVE: The objective of the study was to investigate in vitro and in vivo the possible involvement of AVP in the physiopathology of primary aldosteronism. DESIGN: The design of the study included immunohistochemical, pharmacological, and molecular studies on aldosterone-producing adenoma (APA), followed by a monocentric, crossover trial of the orally active V(1a) receptor antagonist, SR 49059, in a double blind, randomized, and placebo-controlled fashion. SETTING: The study was conducted at a university hospital and research laboratory. PATIENTS: The study population included eight untreated patients with primary aldosteronism, four with APA and four with idiopathic hyperaldosteronism. MAIN OUTCOME MEASURES: Aldosterone secretion of APA cells in vitro and plasma aldosterone, renin, and ACTH were measured. INTERVENTION: SR 49059 (200 mg once daily) or placebo was administered during two 1-wk treatment periods separated by a 2-wk washout. RESULTS: We observed the occurrence of AVP-containing cells in APA tissues. Administration of AVP to perifused APA cells induced an increase in aldosterone production, which was inhibited by a specific V(1a) antagonist. RT-PCR analysis showed the expression of V(1a) receptor mRNA in most APAs studied. In APA patients, SR 49059 did not induce any effect on basal aldosterone secretion but provoked a plasma aldosterone response to orthostatism (P < 0.03) and strengthened the positive correlation between plasma aldosterone and ACTH. CONCLUSIONS: The present study indicates that functional V(1a) receptors are present in APA and suggests that AVP may exert an autocrine/paracrine control of aldosterone secretion in APA tissues.


Assuntos
Aldosterona/metabolismo , Hiperaldosteronismo/metabolismo , Vasopressinas/fisiologia , Adenoma/metabolismo , Hormônio Adrenocorticotrópico/sangue , Aldosterona/biossíntese , Estudos Cross-Over , Método Duplo-Cego , Feminino , Imunofluorescência , Antagonistas de Hormônios/farmacologia , Humanos , Imuno-Histoquímica , Indóis/farmacologia , Masculino , Pessoa de Meia-Idade , Neoplasias Hipofisárias/metabolismo , Pirrolidinas/farmacologia , RNA/biossíntese , RNA/genética , Receptores de Vasopressinas/metabolismo , Reação em Cadeia da Polimerase Via Transcriptase Reversa
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA